| Literature DB >> 35208899 |
Timothé Guilavogui1,2, Nausicaa Gantois1, Gaël Even3,4, Jeremy Desramaut1, Ellena Dautel1, Constance Denoyelle1, Fode Ibrahima Cissé5, Salif Cherif Touré5, Bakary Luther Kourouma6, Manasi Sawant1, Magali Chabé1, Gabriela Certad1,7, Eric Viscogliosi1.
Abstract
Blastocystis sp. is a single-celled parasite estimated to colonize the digestive tract of 1 to 2 billion people worldwide. Although it represents the most frequent intestinal protozoa in human stools, it remains still under-investigated in countries with a high risk of infection due to poor sanitary and hygiene conditions, such as in Africa. Therefore, the present study was carried out to determine the prevalence and subtype (ST) distribution of Blastocystis sp. in the Guinean population. For this purpose, fecal samples were collected from 500 individuals presenting or not digestive disorders in two hospitals of Conakry. Search for the parasite in stools was performed by real-time PCR targeting the small subunit rDNA gene followed by sequencing of the PCR products for subtyping of the isolates. A total of 390 participants (78.0%) was positive for Blastocystis sp. Five STs were identified in the Guinean cohort (ST1, ST2, ST3, ST4 and ST14) with varying frequency, ST3 being predominant. Among them, ST4 was found in only two patients confirming its global rarity in Africa whereas infections by ST14 were likely the result of zoonotic transmission from bovid. No significant association was detected between Blastocystis sp. colonization or ST distribution and the symptomatic status of Guinean subjects or the presence of digestive symptoms. In contrast, drilling water consumption represented a significant risk factor for infection by Blastocystis sp. Predominance of ST3 coupled with its low intra-ST diversity strongly suggested large-scale human-to-human transmission of this ST within this cohort. In parallel, the highest intra-ST diversity of ST1 and ST2 was likely correlated with various potential sources of infection in addition to anthroponotic transmission. These findings highlighted the active circulation of the parasite in Guinea as reported in some low-income African countries and the necessity to implement prevention and control measures in order to limit the circulation of this parasite in this endemic geographical area.Entities:
Keywords: Africa; Blastocystis sp.; Guinea; SSU rDNA sequence; intestinal protozoa; molecular epidemiology; real-time quantitative PCR; subtyping; transmission; zoonosis
Year: 2022 PMID: 35208899 PMCID: PMC8876712 DOI: 10.3390/microorganisms10020446
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Map of Guinea showing the Conakry area where the study was conducted and the residence of the subjects enrolled in this study; the black box frames the two sites of participating hospitals: Confessional Health Center Anastasis and National Hospital Ignace Deen of Conakry.
Distribution of participants according to their place of residence and the attendance to the two selected hospitals.
| Residence Place | Confessional Health Center Anastasis | National Hospital | Total |
|---|---|---|---|
| Boffa | 0 | 1 | 1 |
| Conakry | 177 | 228 | 405 |
| Coyah | 0 | 2 | 2 |
| Dubréka | 0 | 12 | 12 |
| Kamsar | 0 | 2 | 2 |
| Kassa | 0 | 1 | 1 |
| Kindia | 72 | 2 | 74 |
| Labé | 0 | 1 | 1 |
| Nzérékoré | 1 | 0 | 1 |
| Tanéré | 0 | 1 | 1 |
|
|
|
|
|
Prevalence and ST distribution of Blastocystis sp. in the two Guinean hospitals screened in the present study.
| Hospitals | Samples | Positive Samples (n) | Prevalence(%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ST1 | ST2 | ST3 | ST4 | ST14 | MI a | ||||
| Confessional Health Center Anastasis | 250 | 194 | 77.6% | 62 | 27 | 49 | 1 | 7 | 48 |
| National Hospital Ignace Deen | 250 | 196 | 78.4% | 34 | 39 | 68 | 1 | 3 | 51 |
|
|
|
|
|
|
|
|
|
|
|
a MI, Mixed infections.
Prevalence and ST distribution of Blastocystis sp. according to the residence place of participants.
| Residence Place | Samples | Positive Samples (n) | ||||||
|---|---|---|---|---|---|---|---|---|
| ST1 | ST2 | ST3 | ST4 | ST14 | MI a | |||
| Boffa | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Conakry | 405 | 314 | 69 | 54 | 100 | 1 | 10 | 80 |
| Coyah | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
| Dubréka | 12 | 9 | 2 | 1 | 0 | 0 | 0 | 6 |
| Kamsar | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Kassa | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Kindia | 74 | 59 | 23 | 11 | 13 | 1 | 0 | 11 |
| Labé | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Nzérékoré | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Tanéré | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
|
|
|
|
|
|
|
|
|
|
a MI, Mixed infections.
Figure 2Alignment of partial SSU rDNA gene sequences from Blastocystis sp. ST1 (A), ST2 (B), and ST3 (C) isolates. Only the variable positions identified in the compared domain of the SSU rDNA gene for these three STs highlighted as largely predominant in the present survey are shown in this alignment. The positions of variable positions with respect to the reference sequences (genotypes ST1-1, ST2-1 and ST3-1) are indicated above the alignment (vertical numbering). Nucleotides identical to those of the reference sequences are represented by dashes and gaps are represented by asterisks. All the genotypes identified for each ST are indicated on the left of the alignment. On the right of the alignment are reported the total number and percentage of isolates identified in our study for each genotype.
Prevalence and ST distribution of Blastocystis sp. in African countries (completed from [10]).
| African Region/Countries | Prevalence | Number of Subtyped Isolates | Subtyping Method | Mixed Infections d | Reference | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST1 | ST2 | ST3 | ST4 | ST5 | ST6 | ST7 | ST10 | ST14 | ||||||
|
| ||||||||||||||
| Tunisia | NA a | 61 | Sequencing | 18 | 10 | 31 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | [ |
| Libya | 28.0% | 38 | Sequencing | 19 | 3 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | [ |
| Libya | NA a | 48 | Sequencing | 26 | 13 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 36 | PCR-STS b | 6 | 0 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 110 | PCR-STS b | 15 | 0 | 49 | 0 | 0 | 33 | 13 | 0 | 0 | 0 | [ |
| Egypt | NA a | 33 | Sequencing | 0 | 0 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 21 | Sequencing | 4 | 4 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 44 | PCR-STS b | 8 | 0 | 24 | 0 | 0 | 8 | 4 | 0 | 0 | 0 | [ |
| Egypt | NA a | 22 | Sequencing | 4 | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 53 | PCR-STS b | 16 | 4 | 30 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 100 | RFLP c | 0 | 0 | 84 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 2 | PCR-STS b | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 51 | PCR-STS | 9 | 2 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Egypt | NA a | 6 | Sequencing | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Algeria | NA a | 3 | Sequencing | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| ||||||||||||||
| Nigeria | 84.0% | 127 | Sequencing | 51 | 42 | 33 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | [ |
| Nigeria | 49.0% | 22 | Sequencing | 10 | 0 | 9 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | [ |
| Nigeria | 55.0% | 18 | Sequencing | 8 | 4 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | [ |
| Côte d’Ivoire | 58.2% | 64 | Sequencing | 32 | 14 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Côte d’Ivoire | 70.0% | 0 | NA a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Côte d’Ivoire | 87.0% | 0 | NA a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Liberia | 70.0% | 25 | Sequencing | 7 | 7 | 8 | 3 | 0 | 0 | 0 | 0 | 0 | 5 | [ |
| Senegal | 80.4% | 453 | Sequencing | 113 | 226 | 107 | 0 | 0 | 0 | 3 | 2 | 2 | 135 | [ |
| Senegal | 100% | 103 | Sequencing | 29 | 21 | 51 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Mali | 49.7% | 0 | NA a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| ||||||||||||||
| Angola | 25.6% | 75 | Sequencing | 23 | 23 | 27 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | [ |
| Cameroon | 88.2% | 65 | Sequencing | 23 | 9 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Cameroon | 75.4% | 135 | Metagenomics | 45 | 32 | 57 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| ||||||||||||||
| Tanzania | 81.8% | 34 | Metagenomics | 11 | 13 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Tanzania | 55.6% | 15 | Metagenomics | 1 | 12 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Tanzania | 60.9% | 92 | Sequencing | 36 | 28 | 27 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | [ |
| Tanzania | NA a | 6 | Sequencing | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Tanzania | 53.0% | 8 | Sequencing | 2 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Sudan | 47.0% | 29 | Sequencing | 14 | 5 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| ||||||||||||||
| Madagascar | 64.5% | 158 | Sequencing | 80 | 36 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | [ |
| Mozambique | 14.1% | 154 | Sequencing | 35 | 35 | 70 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
| Malawi | 69.6% | 25 | Metagenomics | 7 | 6 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | [ |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
| |||
a NA, not applicable. b STS, subtype-specific sequence-tagged site. c RFLP, restriction fragment length polymorphism. d Mixed infections with undetermined STs.